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Summary Docetaxel is a new taxoid with clinical activity in breast and lung cancer. Using docetaxel-sensitive and -refractory mammary and
pancreatic munne tumours, as well as human-derived neoplasms, we investigated if a determinant of docetaxel sensitivity could be found at
the level of its mechanism of action. Because microtubules represent the cellular targets of the drug, we studied their heterogeneity in the
tumour models to try to explain the differences in drug sensitvity. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of the
expression of microtubular components showed that levels of M34-tubulin and Tau mRNAs were higher in the munne sensitive neoplasms
than in the refractory ones. It was also found that Tau protein levels differed markedty among the tumours. In the human-derived sensitive
neoplasm. J-tubulins and some Tau isoforms were found to be more abundant than in the resistant one. Westem blot analysis of MAP2
revealed the presence of several immunoreactive species. Some of these polypeptides were also found in higher amounts in the docetaxel-
sensitive tumours. The possible meaning of these correlations is discussed in connection with the regulation of microtubule dynamics.
Keywords: docetaxel sensitivity/resistance; microtubules; microtubule-associated protein
Docetaxel is a new taxoid which is currently tested in phase III
clinical trials. In preclinical exvaluation. docetaxel w-as found to
hax-e a broad spectrum of efficacx (Van Oosterom et al. 1995). It
exhibits hiah lexels of activitv in both first- and second-line breast
cancers. including anthrac -cline-resistant neoplasms and non-
small-cell lung cancers. Howexer. wxithin a aiven indication. not
all patients respond totherapy (Bisserx et al. 1991. 1995a. 1995b).
Taxoids. represented by docetaxel (Taxotere) and paclitaxel
(Taxol). haxe the propertx of increasinc microtubule stabilitx to
lexels incompatible with normal cell metabolism. P-Tubulins are
thought to be the major targets of these drugs (Combeau et al.
1994) and. consequently. several prexvious studies have reported
alterations in the expression level of ,B tubulins in cell lines
resistant to paclitaxel. Jaffrezou et al (1995) reported the oxer-
expression of 5-tubulin (class IVa) in cells derixed from an
er-throleukaemic cell line (K562) that w-ere selected for their
resistance to paclitaxel. Haber et al (1995) found increased lexels
of MP32-tubulin in a series of paclitaxel- and docetaxel-resistant
J774.2 cell lines. However. the formal implication oftubulin oxer-
expression in resistance to taxoids has not been firmlx established.
In addition. it has been show-n that taxoids. as well as other micro-
tubule-damaging drugs. are able to induce Bc12 phosphorylation
and apoptosis in cancer cells. Bc12 has thus been defined as the
-uardian of microtubule intet'itx- (Haldar et al. 1997).
We have identified responsixe. refractory and resistant model
tumours within breast and pancreatic cancers. Refractorx tumours
do not respond to therapy (innate resistance). whereas the resistant
ones are neoplasms that initially responded to therapy and then
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acquire resistance to the agent (Bisserx et al. 1991. 1995a. 1995b).
Using sex-eral freshly explanted docetaxel-sensitive. refractorx and
resistant tumours. ourgoal w-as to in estigate wxhether an alteration
of microtubule components could explain their different drus
sensitix ities. We haxe therefore studied the expression of sexeral
microtubule-associated proteins (Tau. MAP2 and MIAP4) and 5-
tubulins bv usinc a semiquantitatix e non-competitixe RT-PCR
approach and by Western blot analx-sis.
MATERIALS AND METHODS
Tumour models and mice
Docetaxel wxas exaluated for its anti-tumour actixitx in xixo against
sexven tumour models including mammarx adenocarcinomas
MA13/C. NMA16/C. MA44 of murine origin. the human Calcl8 and
Calcl8/FXT xenografts and murine pancreatic ductal adenocarci-
nomas P03 and P02. These tumours are in the National Cancer
Institute frozen tumour repositorx- which is maintained at the
Frederick Cancer Research Facilitv (Frederick. MID. USA) and hax-e
a code identification number. a detailed description and a list ofrefer-
ences. except forCalc18 and Calc18AfXT. A-hich wxere a rift from JF
Riou. Rhone-Poulenc-Rorer. Vitnx. France. Tumours xxere main-
tained in the mouse strain of onmmin. i.e. C3HJHeN for the munrne
mammarv tumours and C57B1/6 for the pancreatic ones. The human
tumours wxere xenocrafted into Swxiss nu/nu nude mice. For
chemotherapy trials. the murine mammarx tumours x ere trans-
planted into the strain of origin and the pancreatic tumours into
B6D2F1 mice. xxhich is an Fl hN-bn'd. C3H/HeN mice xxere bred at
Charles Rixer (Cl6on. France) from strains obtained from Charles
Rixer Laboratories (Wilminrton-MA. USA). and C57B1/6. B6D12F
and Sxxiss nu/nu were bred at Iffa Credo (L'Arbresle. France) from
strains obtained from The Jackson Laboratories (Bar Harbor. ME.
USA). The mice xxere supplied food and wxater ad libitum.872 R Veitia et al
Drugs
In xi-xo studies w-ere carried out using a formulation of docetaxel
in ethanol polysorbate 80 (50:50. v/xv). After dilution. the final
concentrations were 5%r ethanol. 5%k polvsorbate 80 and 90%s of
5s% glucose in water. For chemotherapy trials. docetaxel provided
bx the Rh6ne-Poulenc-Rorer laboratory (Vitrv sur Seine. France)
was administered intraxenously(iv . The experiments and data
analy ses A-ere performed according to protocols described prexi-
ously (Bissery et al. 1991. 1995a. 1995b(.
The actixit- end point used to assess subcutaneously implanted
solid tumours A-as tumour growth inhibition (TIC, Where T and C
are the median tumour weight ofthe treated and the control groups
respectixelx ) In cases of hinh anti-tumour actixity. the txwo
following end points were also used: the tumour growth delay
[T-C. A-here T and C are the median times. in days. required for
the treatment group and the control group tumours to reach a
predeterrnined size (750-1000 mgh] and the log, cell kill. which is
the logarithm of the total number of cells killed bv treatment. A
compound is considered highly actixe if the locg cell kill total is
> 2.8 and is considered inactixe ifthe log cell kill total is < 0.7. For
advanced-stage tumours. regressions were either partial (more
than 50%7e reduction in tumour mass) or complete (rearessions
below- the palpation limit). Complete regressions were included in
the partial ones. Toxicity Nx-as based on drug deaths (> 20%7c) or a
wei2ht loss in excess of 20%/s.
Total RNA extraction
RNA w-as extracted from about 0.5 , ofsexeral tumour fragments
using, a guanidinium thiocyvanate-acid phenol extraction method
(Chomczy-nski and Sacchi. 1987). The RNA pellets were resus-
pended in 0.5 ml of sterile water. The RNA was treated with
DNAase I (IOU m- RNA) for 1 h at 37 C to eliminate any
possible DNA contamination (RNAase-free DNAase I.
Boehringer. Mannheim. German ).
cDNA synthesis
cDNA sxnthesis >-as carried out from 2.5 tg of DNAase I-treated
RNA (from at least tw-o independent tumour preparations) using the
Superscript II enzyme (Life Technologies. Gaithersburg. MD. USA)
follo ing the manufacturer's instructions. After an ethanol precipi-
tation step. the cDNA A-as resuspended in 300 .l of sterile w-ater.
RT-PCR
All primers for PCR were designed from the sequence data avail-
able in the literature and the Genbank database (accession
numbers in brackets). F and R stand for fonAard and reverse
primers respectively. Sequences are gixen in the 5' -s 3' direction
and the expected lengths ofthe different amplicons are indicated in
brackets.
For tubulins
MaIMl13445): TuAlF:
TGCCGCGAACGAGCAAC/TCuA 12R:
GTCATCTCCTCCCCCAAT (158 bp)
Ma2(M 3446): TuA2F: CCTCGCCTTCTAACCCGfIuA 12R:
GTCATCTCCTCCCCCAAT (165 bp)
M34M28730): TuB4F*: GTCGACCTGGAACCCGITuB4R:
CCACCGTGTCAGACACC (342 bp)
For MAPs
Tau (see text): TF: GCCGAAGAAGCAGGCATCITR:
GCCCTTCTGGGCCGGAGA (186 bp)
MAP2(M21041) M2F: GGTGACTTGGCTCAGGCT/M2R:
CGTTAGGAGTAGCTGGGG (433 bp)
MAP4(M72414) M4F: GGAGGGGAATAACACTGC/N14R:
TGGGGCTCCCACAGACC (324 bp)
Absence of genominc DNA contamination was verified bv
RT-PCR with pnrmers (ClInhF: 5'-TGGCCTCCAGGCTGACCC-
CACTGA-3' and ClnhR: 5'-TGTFTATTGTGATG(GCTACACT-
GGT-3' able to amplihf both cDNA and genomic DNA coding for
the munine Cl inhibitor. The expected lengths of the products are
221 bp for amplified cDNA and 1200 bp for genomic DNA.
The primers used to amplify the different M>-tubulin isoforms
were those described by Haber et al (1995). w-ith the exception of
the rexerse primer for MfVt-tubulin. Another specific forward
primer for this tubulin (TuB4F*) w xas used to confirm the results
discussed belowx. The expected amplicon lengths for M1-tubulins
were 146. 171. 145. 572 and 194 from M1l to MB5-tubulin
respectixely.
Non-competitixve RT-PCR w-as performed on a Perkin Elmer
thermal cycler using the following conditions: for Tau and ClInh.
5 min at 94 C then 1 min at 94 C. 1 min at 58 C and 1 min at 72-C
for a number of cycles that wxill be indicated w-hen necessar-
follow-ed by a final extension step for 10 min at 72:C: for MAP2.
MAP4 and all tubulins. 5 min at 94 C then 30 s at 95 C. 30 s at 55-C
Table 1 In vivo actvity of standard clinical agents against earty-stage mouse tumours
Agent
Tumour TXT Vinc Vbl Nvib CPA CDDP VP-16 Adr 5-Fu Ara-C
P03 4+ 2+ 2+ 4+ 3+ - -
P02 - - + +,'- - - - - - -
MA16/C 4+ 2+ 3+ + 3+ 4+ 3+ 2+
MA13/C 4+ + 2+ 4+ 4+ 3+ 2+
MA44 +/- +- + + +
TXT. Taxotere: Vinc. vincnstine: Vbl. vinblastine: Nvib. vinorelbine: CPA. cydophosphamide: CDDP. cisplatin: VP-16. etoposide: Adr. adriamycine: 5-Fu.
5-fluorouracil: Ara-C. palmo-ara C. Actity rating: 4+. highly active (log cell kill > 2.8). 3+. highly active (log cell kill = 2.0-2.8): 2+. active (log cell kill = 1.3+1.9):
+. active (log cell kill = 0.7-1.2 for s.c. tumours): -. inactive (log cell kill < 0.7).
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and 30 s at 72'C for a number of cvcles that A-il be indicated %x-hen
necessarv. followed by a final extension step for 10 min at 72'C.
Quantification of RT-PCR products
In order to achieve an accurate quantification of mRNA. the
number of PCR cxcles was chosen in a wav that w-ould preserx e a
linear relationship betx-een input cDNA and final RT-PCR
product. For tubulins (Mal. 2. MJ2. 3 and 5) the number ofcxcles
>-as 21. wxhereas for the scarcer MP number of cycles was 33.
After agarose gel electrophoresis. the PCR products were stained
with SxbrGreen II (FMC Bioproducts. Rockland. ME. USA) as
indicated by the manufacturer and then semiquantified in a
Fluoroimager Sx stem (Molecular Dynariics. Sunnx Xale. CA.
USA). All RT-PCR reactions and quantifications w-ere carried out
three times.
Immunoblot analysis
Small pieces of each tumour w-ere homogenized in RIPA buffer
[10 mm Tris-HCl. 0.15 M\ sodium chloride. 5 m\t ethylenedi-
aminetetracetic acid (EDTA . 1% '7 NP40. 0.1%7c sodium dodecy 1
sulphate (SDS). 1Il sodium desoxycholate and 2 mm¶ phenv1-
methylsulphonyl fluoride]. In some cases (indicated). tumours
were homogenized in a detergent-enriched RIPA buffer w-ith. in
addition. Il Triton X-100. 2% SDS and a cocktail of protease
inhibitors. After a clarification step by centrifugation. samples
w-ere electrophoresed in a 10%7 PAGE-SDS (Novex. San Diego.
CA. USA). Transfer onto nitrocellulose membranes was carried
out following the manufacturer's instructions (Novex).
Immunoblots were performed wvith antibodies against ca-tubulin
(monoclonal N356. Amersham. UK). SVtubulin (monoclonal
N357. Amersham. Arlington Heights. IL. USA). 4-tubulin (clone
ONS 1A6. Sigma). with two different polvclonal antibodies
directed against the neuronal Tau proteins [one produced in our
laboratorv (Vantard et al. 1991) and TRS 1-2. a -ift from Dr R
Maccioni. Santiago. Chile] and the MAP2 monoclonal antibodv
152 produced in our laboratory (Kalil et al. 1988). Quantification
of tubulins >-as carried out on a Phosphorimager (Molecular
Dynamics) after using, a 'I-labelled second antibody (Amersham.
Arlington Heights. IL. USA). Tau and MAP2 (related) proteins
were detected by Enhanced Chemiluminiscence (ECL.
Boehringer. Mannheim. Germany).
RESULTS
In vivo anti-tumour efficacy of docetaxel
In this study. docetaxel w-as exaluated i.%-. acainst murine
mammarv (MA13/C. MA16/C and MA-H) and pancreatic (P02
and P03) tumours. Their characteristics and response to
chemotherapy are summarized in Table 1. The human-derived
breast tumours Calc18 and Calc1 8/TIXT. also used in our studies.
and which are currentlI beine characterized. came from cell lines
sensitive and resistant to docetaxel respectively (Riou et al. 1994).
Docetaxel is a schedule-independent drug (Bisser- et al. 1991.
1995b) that was found to be clearly active on three out of four
mammaix tumours (the murine MA16/C. MA13/C and the human
Calc18) and one out oftx o murine pancreatic tumours (P03 . w-ith
a high rate of complete tumour regressions of advanced-stage
disease (100%7c for MA16/C. 60%7 NMA13/C and 83%e for P03)
(Table 2). Two of the murine tumour models w-ere found to be
refractory to docetaxel. the mammarv MA44 and the pancreatic
P02. when treated at an early stage (Table 1). It is interesting to
note that P02 is also refractors to docetaxel-unrelated drugs
(Table 1). Howexver. the P-glycoprotein (involved in producing a
multidrug resistance phenotype: Arceci et al. 1993) has not been
shown to be relex-ant for this model (Kessel and Corbett. 1985:
Priebe et al. 1992).
Analysis of tubulin expression in the murine tumours
The RT-PCR analysis ofthe expression oftubulin isotypes show-ed
no differences in the mRNA levels correspondinc to tubulins M132.
MP3 and M05 among the different tumours. when Mcl- and
Mat2-tubulins w-ere taken as a reference for the quantification. In
contrast. the sensitix e tumours w-ere characterized by higher lex els
Table 2 In vivo anti-tumour activity of docetaxel against mammary and pancreatic adenocarcinomas
Highest nor-toxic Schedule Total dose TCa T-Cb Totaic Activityd
Solid tumours s.c. i.v. dosage (days) (mg kg-') (%) (days) (log cell kill) rating
(mg kg-' dose-')
Pancreas
P02 32.2 3,5.7 96.6 39 - - + -
P03 earty 20.5 3.5.7.9 82.0 0 - 6/6 cures ++++
P03 advanced 18.0 22.24,26.28 72.0 - 21.4 1.8 5/6 CR'
Mammary
MA16/C advanced 10.8 7.9.11 32.4 - 14.3 2.9 515 CR
MA13/C earty 14.2 3,5.7 42.6 0 36.0 4.3 + +
MA13/C advanced 15.0 24,27.30 45.0 - 23 9 2.5 3/5 CR
MA44 earty 22.0 3.5.7 66.0 39 - - +/-
Human Calcl8 palpable 32.2 7.10.13 96.6 - 40.8 2.1 +++
Human Calc18JTXT 20.0 7,10.13 60.0 51 - -
aT/C (0o). for solid tumours = 100 x median tumour weight of the treated/median tumour weight of the controls. nT-C (days) = median time in days required for
the treatment group T and the control group C tumours to reach a predetermined size. :log cell kill = T-C in days/3.32 x tumour doubling time of control mice.
'Actvity rating: i1+++i+. highty active (log cell kill > 2.8): s +, highty active (log cell kill = 2.0-2.8); ++. active (log cell kill = 1.3-1.9): +. active (log cell kill = 0.7-1.2
for s.c. tumours): -. inactive (log cell kill < 0.7). eCR. complete regressions. The 32.2 mg kg-' dose produced a 460° T/C (inactive following NCI standards) but
was found to be toxic resulting in excessive body weight loss (19.20o).
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FKgure 2 Typical results of RT4PCR for MAP 2 and Tau (35 cycles). The
PCR was carried out on total cDNAs containing equal amounts of Mal1- and
Ma2-tubuAin cDNAs. Vertical arrows indicate the docetaxel-refractory tumours
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Figure 1 Analysis of Mal, Ma2 and M(4 tubulins mRNA expression.
(A) Typical RT-PCR results (25 cycles for Mal, Ma2-tubulins, 33 cycles for
M-thubulin). Vertcal arrows indicate te docetaxelefractory tmours.
(B) Semiquanttatie analysis of mRNA evels presented as te rato between
the figure obtaied after the Fluorinag analysis for the specific tumour and
fis value for MA44 (docetaxel refractory) in te case of mammary neoplasms.
For the pancreatc ones Fe rato was estblshed between P03 and P02
of M4-tubulin (class IVa) mRNA (Figure 1), although we could
not find significant differences at the protein level (data not
shown). No amplification could be obtained forMPl-tubulin.
Analysis of the expression of microtubule-associated
proteins in the munne tumours
The expression of microtubule-associated proteins (MAPs) was
also considered at both the mRNA and the protein level. The tran-
script analysis by RT-PCR of mammary and pancreatic tumours
demonstrated that the mRNA coding for MAP2 (Figure 2). consid-
ered to be neuron specific (Lewis et al. 1986). was also expressed
in these non-neural tissues. As shown in Figure 2. the amount of
MAP2 mRNA did not correlate with the docetaxel sensitivity of
the neoplasms. This was also true for MAP4 (results not shown).
To study Tau mRNA expression. we designed primers that were
able to amplify most of the isoforms: two variants (Genbank Al:
U12915 and U12914) expressed in the liver (Kenner et al, 1994)
and two other isoforms (M18775 and M18776) known to be
expressed in mouse brain (Lee et al. 1988). Interestingly.
docetaxel-sensitive tumours showed higher levels of Tau mRNA
(Figure 2). These results were ftuther confirmed with the forward
primer TF: 5-GCTCGTGTGGCCAGCAAA-3 which is able to
amplify all known Tau isoforms in combination with TR. to yield a
Figure 3 Tau protei from munne mamnary and pancreabc tumours
detected by Westem blot analysis. Volumes of RIPA extacts containin
similar amount of a-bibuin (also detected by ECL) were baded in each
Lane. Tau proteins were detected with polycona antbodis directed against
neuronal Tau. (A) Antbody produced as descrbed by Vantard et al (1991);
(B) antbody TRS 1-2. The docetaxel-refractory neoplasms are distinguished
by vertcal arrows. SAd: Adult rat brain crude exta
product of 120 bp. The relative amount of Tau proteins was
measured by analysing tumour extracts (classical RIPA) containing
similar amounts of a-tubulin. Immunoblotting with a polyclonal
antibody directed against brain Tau (Vantard et al, 1991) revealed a
higher level ofTau-related polypeptides in the sensitive neoplasms
(MA13/C. MA161C and P03) than in the refractory ones (MA44
and P02) (Figure 3A and C). This result was conffimed with the
polyclonal antibody TRS 1-2 (Cambiazo et al. 1995) (Figure 3B
and C). To investigate the possibility that some Tau proteins might
remain insoluble in the extracts obtained with the classical RIPA
buffer. tumours were also treated with a detergent-enriched RIPA
buffer. Some Tau-related polypeptides were found to be signifi-
candy more abundant in the tumours sensitive to docetaxel. As
shown in Figure 4A and B, the higher levels of Tau-like polypep-
tides in the sensitive mammary adenocarcinomas consisted mainly
of a species of high molecular weight (125 kDa). However, in the
refractory tumour (MA44). some polypeptides located towards the
higher molecular weights within the Tau region were more abun-
dant than in the sensitive neoplasms.
By using a monoclonal antibody directed against brain MAP2.
the presence ofrelatedpolypeptides was established in the different
murine tumours. As shown in Figure 5A-C, the classical 300-kDa
MAP2 was not found. probably because ofits proteolytic fragmen-
tation. and the relative amounts of the different polypeptides
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Figure 4 Tau-related proteins from murine mammary and pancreatic tumours extracted with a detergent-enriched RIPA buffer. For equal amounts of a-tubulin
loaded in each lane, Tau levels (polyclonal antibody, Vantard et al, 1991) were compared between MAl 3/C and MA44 (A) and MAl6/C and MA44 (B). The
asterisks indicate the Tau-related protein of 125 kDa. Vertical arrows indicate the docetaxel-refractory tumour line (MA44). Sad: adutt rat brain crude extract
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Figure 5 MAP2-related proteins from murine mammary and pancreatic adenocarcinomas. MAP2-related polypeptides were detected using the monocdona
antibody 152 produced in our Laboratory (Kalil et al, 1988) (for equal amounts of a-tubulin in each Lane). The asterisk indicates the 364kDa fragment while the
arrows indicate the 18-20 kDa fragments
changed follow'ing the docetaxel-sensitivitv of the tumour. A
fragpment of about 36 kDa and a doublet of 18-20 kDa were
significantly more abundant in the tumours sensitive to the drug
(MA16/C. MAI3/C and P03).
Analysis of microtubular proteins in human-derived
tumours sensitive to, or with acquired resistance to,
docetaxel
Mammary tumours ofhuman origin either sensitive to (Calc18) or
resistant to (Calcl8/17XT) docetaxel were also analysed after
extraction ofproteins with a detergent-rich RIPA buffer (Figure 6).
Tau proteins displayed a complex pattern involving molecular
species which were expressed in different amounts im the two
types of tumour. The monoclonal antibody Taul. which does not
recognize the highly phosphorylated Tau of the Alzheimer disease
tangles (Kosik et al. 1988). revealed a major band which was more
abundant in the sensitive neoplasm. The MAP2-related fragments
were also found to be different in the two types of tumour (not
shown). In addition. the global amount of I-tubulin was found to
be more abundant in the sensitive tumour (Calc18) after normal-
ization for equal amounts of a-tubulin.
DISCUSSION
Docetaxel (Taxotere) is an anti-microtubular agent with clinical
activity against various cancers. Using docetaxel-sensitive and
-refractory mammary and pancreatic murine tumours and human-
derived neoplasms. our goal was to investigate if a determinant of
docetaxel sensitivity could be found at the level of its mechanism
of action. In the case of the docetaxel non-sensitiv-e models.
we investigated the drug-refractorv tumours P02 and MA44
and a tumour model with acquired resistance to docetaxel.
Calc 18/EXT.
The murine sensitive tumours studied (MA16/C. MA13/C and
P03) were characterized by a higher level of expression of class
IVa tubulin(MP4) mRNA. As the expression ofclass IV tubulin is
thought to be restricted to neuronal tissue and tumour cell lines
(Lee et al. 1984: Cowan et al. 1986). the increased level that we
detected in the docetaxel-sensitive tumours is likely to originate
from the malignant cells. We could not find relevant differences
among tumours in theMP4tubulin protein level (data not shon).
However. we cannot exclude the possibility of an altered expres-
sion of this tubulin isoform. Because the antibody used to detect
the MP4tubulin was a monoclonal recognizing the C-terminal
portion of the protein. uncontrolled proteolysis of this region and
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Figure 6 Tubulin and Tau content in two human-derived mammary tumours. Volumes of extracts (detergent-enriched RIPA buffer) containing similar amounts
of a-tubulin were loaded in each lane. Tau were detected with a polyclonal antibody (Vantard et ai, 1991) and the monocknW antibody Taul
possible cross-reactions with other tubulin isotypes may have
introduced a source ofvariability in our results.
We examined the expression level of different MAPs by taking
a-tubulin to normalize for the amount of microtubule transcripts
and proteins. Although we cannot provide formal proof. the
increased levels ofTau found in the docetaxel-sensitive neoplasms
may represent one ofthe factors responsible for the drug sensitivity
of the tumours. We have recently described the role of these
proteins in modulating microtubule alterations induced by
docetaxel (Fromes et al. 1996). In addition, it is known that the
ectopic expression ofTau in non-neural cells increases microtubule
stabilization (Lee et al. 1992). Furthermore, different levels ofTau
proteins may alter the ratio ofpolymerized versus non-polymerized
tubulin, and it has been shown that lowering the net amount of
polymerized tubulin is sufficient to confer taxol acquired resistance
(Cabral et al, 1989). Our data also showed a significant expression
of a Tau-related polypeptide. of about 125 kDa. in the sensitive
tumours. which may correspond to the high molecular weight
isoform found in the mature peripheral nervous system and there-
fore may be involved in modulating microtubule stability (Couchie
et al. 1992). The shift of several Tau isoforms to the higher molec-
ular weights within the Tau region in the murine refractory tumour
MA44 suggests that the state ofphosphorylation ofthese proteins is
more important in this tumour (Figure 4). Interestingly. highly
phosphorylated Tau has a poor capacity to be inorporated in
microtubules and may generate unstable structures that are less
sensitive to the stabilizing effect of docetaxel (Lindwall and Cole.
1984; Correas et al. 1992). When comparing Figures 3 and 4. it can
be seen that several Tau-related polypeptides present in the murine
refractory tumours were extracted in detectable amounts only upon
using a detergent-enriched REPA buffer. It is possible that
cytoskeletal proteins of tumoral epithelial cells are not easily
extractable because ofthe abundance of afibrous and dense stroma
surrounding tumoral cells. It is also likely that several Tau isofonns
may aggregate by a self-association reaction similar to that
described by de Ancos et al (1993).
A higher level of several MAP2-related polypeptides was
detected in the docetaxel-sensitive tumours, particularly a frag-
ment of approximately 36-38 kDa. Interestingly. the 36-kDa
tubulin-binding domain of MAP2 has some Tau-like properties
and has been shown to modulate the effect of some anti-
microtubular drugs such as vinblastine (Fellous et al. 1994).
We have also investigated the behaviour of microtubule compo-
nents in two types of tumours derived from a human breast carci-
noma: Calc18. sensitive to docetaxel. and Calc 18TfXT. resistant to
the drug. The latter came from acell line overexpressing theMDRJ
gene and veraparnil was able to reverse its docetaxel resistance
(Riou et al, 1994). Consequently. the tumour Calcl8/1XT moder-
ately expressed the P-glycoprotein (data not shown). In spite of
this. we showed that frtubulin was less abundant in the resistant
neoplasm when using a-tubulin to normalize for the amount of
microtubule proteins. This may reflect the decreased level of >-
tubulin mRNAs observed in the Calc18/XT cell line with respect
to the parental Calc18 (Riou et al. 1994). Interestingly, decreased
levels oftubulins have been shown to confer resistance to taxol in
certain cellular models (see Cabral et al. 1989). Using our poly-
clonal antibody directed against Tau (Vantard et al. 1991). we also
observed differences in the expression ofTau-related polypeptides
in both types oftumours. The monoclonal antibody Tau 1. sensitive
to the phosphorylation state ofthe protein, revealed striking differ-
ences between the neoplasms. but a certain variability that was
noticed in the results was probably due to uncontrolled changes
of the Tau phosphorylation state. Immunohistochemical studies
demonstrated that the polypeptides recognized by Taul were
expressed mainly in the sensitive tumours and the epithelial malig-
nant cells (data not shown).
Although the nature ofthe decreased docetaxel sensitivity ofthe
tumours refractory (innate resistance) and resistant (acquired resis-
tance) to the drug are conceptually different, both types of tumour
displayed differences in the expression and modification of some
Tau isoforms. However, other alterations of microtubular compo-
nents specific to each type of tumour may also contribute to
produce the resistant phenotype. i.e. lower levels of J-tubulin in
Calc I8frXT.
In conclusion, the levels ofseveral Tau isoforms in both murine
and human-derived freshly explanted docetaxel-sensitive tumours
and. to a lesser extent. the mRNA levels for MV-tubulin in the
murine tumours can be regarded as markers of sensitivity to the
drug. From a practical point of view. the finding that some Tau
isoforns are not only present in different amounts but also prob-
ably in different phosphorylation states. may allow the use of
specific antibodies on tumour biopsies and may help decide upon
the worth of a taxoid treatment. These findings are now being
evaluated on a broader panel ofhuman tumour samples.
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